FDA approves Gloucester's drug for rare skin cancer
Gloucester Pharmaceuticals received FDA approval for Istodax, a small-molecule treatment for cutaneous T-cell lymphoma. CEO Alan Colowick said the biotech startup plans to introduce the drug in January.
Boston Globe, The | 11/07
This story published in BIO SmartBrief on 11/09/2009
More from SmartBrief:
Celgene to acquire Gloucester Pharmaceuticals
Monday, December 14, 2009
Allos gets FDA approval for lymphoma drug Folotyn
Monday, September 28, 2009
Biotech sector sees jump in acquisitions
Monday, December 14, 2009
Get stories like these delivered daily for FREE:
|
BIO SmartBrief
Designed specifically for biotechnology industry professionals like you, BIO SmartBrief is a FREE daily e-mail newsletter. It provides the latest news and information you need to stay informed about important biotech issues. Learn more |
|